KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Total Liabilities (2016 - 2025)

Sarepta Therapeutics has reported Total Liabilities over the past 15 years, most recently at $2.2 billion for Q4 2025.

  • Quarterly results put Total Liabilities at $2.2 billion for Q4 2025, down 9.29% from a year ago — trailing twelve months through Dec 2025 was $2.2 billion (down 9.29% YoY), and the annual figure for FY2025 was $2.2 billion, down 9.29%.
  • Total Liabilities for Q4 2025 was $2.2 billion at Sarepta Therapeutics, up from $2.2 billion in the prior quarter.
  • Over the last five years, Total Liabilities for SRPT hit a ceiling of $2.7 billion in Q4 2022 and a floor of $2.2 billion in Q3 2025.
  • Median Total Liabilities over the past 5 years was $2.3 billion (2025), compared with a mean of $2.3 billion.
  • Biggest five-year swings in Total Liabilities: rose 24.29% in 2022 and later fell 13.94% in 2023.
  • Sarepta Therapeutics' Total Liabilities stood at $2.2 billion in 2021, then grew by 23.58% to $2.7 billion in 2022, then decreased by 12.33% to $2.4 billion in 2023, then rose by 1.26% to $2.4 billion in 2024, then decreased by 9.29% to $2.2 billion in 2025.
  • The last three reported values for Total Liabilities were $2.2 billion (Q4 2025), $2.2 billion (Q3 2025), and $2.3 billion (Q2 2025) per Business Quant data.